氯沙坦对慢性心力衰竭病人心肾功能的影响  

Effect of losartan on cardiac and renal function in patients with chronic heart failure

作　　者：谭红梅[1] 李玉英[1] 王宋平[1] 祝善俊[1] 

机构地区：[1]第三军医大学新桥医院心血管病研究所,重庆400037

出　　处：《岭南心血管病杂志》2008年第2期120-122,共3页South China Journal of Cardiovascular Diseases

摘　　要：目的探讨氯沙坦对慢性心力衰竭病人心肾功能的影响。方法慢性心力衰竭病人65例,常规治疗组35例,氯沙坦组30例,连续治疗8周。治疗前、后,抽静脉血、留尿,采用免疫比浊法测定血清胱抑素C和尿微量白蛋白水平,酶联免疫分析法测定尿水通道蛋白-2浓度,超声心动图检测病人心脏收缩功能。结果与常规治疗组比较,氯沙坦组病人左心室舒张末期内径显著下降,而左心室射血分数、左心室短轴缩短率显著升高;血清胱抑素C、尿微量白蛋白、水通道蛋白-2较常规治疗组显著下降。结论氯沙坦可改善慢性心力衰竭病人的心功能和肾功能。Objectives To observe the effect of losartan potassium on cardiac and renal function in patients with chronic heart failure （CHF）. Methods 65 patients with CHF were divided into two groups by using a randomized, control and single blind method： losartan potassium group （n = 30） and routine treatment group （n=35）, with a treatment course of 8 weeks for both groups. The level of cystatin C （cys C） in serum, microamount albumin （MA） in urine were measured by immunoturbidimetry, the concentration of aquapofin-2 （AQP-2） was determined by enzyme-linked-immunosorbent assay （ELISA） and heart contractile function was measured by echosoundcardiography before and after treatment respectively. Results Compared with routine treatment group, left ventricular end-diastolic dimension （LVEDd） decreased significantly, while left ventricular ejection fraction （LVEF） and left ventricular fractional shortening （LVFS） increased significantly in losartan potassium group. The levels of cys C in serum and MA, AQP-2 in urine were lower significantly in losartan potassium group than in routine treatment group. Conclusions Losartan potassium can improve cardiac and renal function in patients with CHF.

关 键 词：心力衰竭 心功能 肾功能 氯沙坦 

分 类 号：R541.61[医药卫生—心血管疾病] R972.4[医药卫生—内科学]